The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.

Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Safi advancing manufactured human RBC (mRBC) program for acute bleeding and chronic transfusion indications This DoD award acceler ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

RAD Security, a San Francisco-based provider of security for cloud-focused infrastructure, raised $14 million in Series A ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...